



POLICIES AND PROCEDURE MANUAL

Policy: MBP 105.0

Section: Medical Benefit Pharmaceutical Policy

Subject: VPRIV (velaglucerase alfa)

Applicable line of business:

Commercial	X	Medicaid	
Medicare	X	ACA	X
CHIP	X		

I. Policy:

VPRIV (velaglucerase alfa)

II. Purpose/Objective:

To provide a policy of coverage regarding VPRIV (velaglucerase alfa)

III. Responsibility:

- A. Medical Directors
- B. Medical Management
- C. Pharmacy Department

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards good medical treatment practiced by the general medical community;
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient

Commercial

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicare

Geisinger Gold Medicare Advantage HMO, PPO, and HMO D-SNP plans are offered by Geisinger Health Plan/Geisinger Indemnity Insurance Company, health plans with a Medicare contract. Continued enrollment in Geisinger Gold depends on contract renewal. Geisinger Health Plan/Geisinger Indemnity Insurance Company are part of Geisinger, an integrated health care delivery and coverage organization.

CHIP

Geisinger Health Plan Kids (GHP Kids) is a Children's Health Insurance Program (CHIP) offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

DESCRIPTION:

VPRIV (velaglycerase alfa) is a hydrolytic lysosomal glucocerebrosidase-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult insured individuals with type 1 Gaucher disease.

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

VPRIV (velaglycerase alfa) will be considered medically necessary for the Commercial, Exchange and CHIP lines of business when all of the following criteria are met:

- Physician provided documentation of:
 - a diagnosis of Type 1 Gaucher disease with at least one of the following:
 - Anemia
 - Thrombocytopenia
 - Bone disease
 - Hepatomegaly or splenomegaly
 - AND**
 - Insured individual is 4 years of age or greater **AND**
- VPRIV is recommended by a metabolic specialist with experience in treating Gaucher disease **AND**
- Medical record documentation of therapeutic failure on, intolerance to, or contraindication to Elvelo (taliglucerase alfa) in adults.

AUTHORIZATION DURATION: Initial approval will be for 6 months or less if the reviewing provider feels it is medically appropriate. Subsequent approvals will be for an additional 6 months or less if the reviewing provider feels it is medically appropriate and will require medical record documentation of continued disease improvement or lack of disease progression. The medication will no longer be covered if patient experiences toxicity or worsening of disease.

VPRIV (velaglycerase alfa) will be considered medically necessary for the Medicare line of business when all of the following criteria are met:

- Physician provided documentation of:
 - a diagnosis of Type 1 Gaucher disease with at least one of the following:
 - Anemia
 - Thrombocytopenia
 - Bone disease
 - Hepatomegaly or splenomegaly
 - AND**
 - Insured individual is 4 years of age or greater **AND**
- VPRIV is recommended by a metabolic specialist with experience in treating Gaucher disease

AUTHORIZATION DURATION: Initial approval will be for 6 months or less if the reviewing provider feels it is medically appropriate. Subsequent approvals will be for an additional 6 months or less if the reviewing provider feels it is medically appropriate and will require medical record documentation of continued disease improvement or lack of disease progression. The medication will no longer be covered if patient experiences toxicity or worsening of disease.

LINE OF BUSINESS:

Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

REFERENCES:

1. Vpriv [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; July 2024.
2. Wang RY, Bodamer OA, Watson MS, et al. Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals. American College of Medical Genetics (ACMG). Generics in Medicine; 2011 May; 13(5):457-484 [cited 2023 Dec 27]. Available from: <https://www.sciencedirect.com/science/article/pii/S1098360021047924?via%3Dihub>
3. Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. The Journal of Pediatrics; 2004 January; 144(1):112-120 [cited 2023 Dec 27]. Available from: <https://www.sciencedirect.com/science/article/pii/S002234760300814X?via%3Dihub>

This policy will be revised as necessary and reviewed no less than annually.

Devised: 3/19/2013

Revised: 3/14, 1/20/2015 (added auth duration), 12/23/2022 (LOB carve out), 12/19/23 (Medicaid business segment), 12/31/23 (references added), 12/2/24 (LOB table, taglines)

Reviewed: 1/20/2015, 3/31/16, 3/30/17, 3/29/18, 1/30/19, 1/10/20, 1/9/21, 12/23/21

MA UM Committee approval: 12/31/23, 12/31/24